Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Matrix metalloproteinase inhibitors: current developments and future perspectives.

R Hoekstra1, F A Eskens, J Verweij

  • 1Department of Medical Oncology, Rotterdam Cancer Institute, Daniel den Hoed Kliniek and University Hospital, Rotterdam, The Netherlands. hoekstra@oncd.azr.nl

The Oncologist
|October 25, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Innovation in oncology clinical trial design.

Cancer treatment reviews·2019
Same author

Moving the Frontiers of Cancer Chemotherapy for Solid Tumors by Changing the Scope of Drug Development.

Hematology (Amsterdam, Netherlands)·2016
Same author

Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.

European journal of cancer (Oxford, England : 1990)·2015
Same author

Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules.

Cancer chemotherapy and pharmacology·2014
Same author

Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.

European journal of cancer (Oxford, England : 1990)·2014
Same journal

The Impact of Relative Dose Intensity on pCR in Neoadjuvant Chemotherapy of Muscle-Invasive Urothelial Cancer: a Multicentre Retrospective Study.

The oncologist·2026
Same journal

Prevalence, treatment and survival of Malignant Peripheral Nerve Sheath Tumor in the Danish neurofibromatosis type 1 population.

The oncologist·2026
Same journal

Molecular Tumor Board-Guided Osimertinib Therapy in EGFR L858R/Q701L-Mutant Lung Adenocarcinoma Supported by Functional Validation.

The oncologist·2026
Same journal

Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3.

The oncologist·2026
Same journal

Divergent Biology and Outcomes of Somatic Transformations in Germ Cell Tumors.

The oncologist·2026
Same journal

Modernizing Disease Assessment in Prostate Cancer Trials: The Prostate Cancer Working Group 4 Framework.

The oncologist·2026
See all related articles

Matrix metalloproteinases (MMPs) degrade the extracellular matrix, aiding tumor invasion and metastasis. Matrix metalloproteinase inhibitors (MMPIs) are being developed to target this process, with early clinical studies showing promise for cancer treatment.

Area of Science:

  • Oncology
  • Biochemistry
  • Molecular Biology

Background:

  • Malignant tumors exhibit invasive growth and metastasis, processes facilitated by the enzymatic degradation of the extracellular matrix (ECM).
  • Elevated concentrations of matrix metalloproteinases (MMPs), enzymes crucial for ECM breakdown, are frequently observed in human tumors.
  • The role of MMPs in cancer progression is a significant area of research.

Purpose of the Study:

  • To review the fundamental mechanisms of ECM degradation.
  • To emphasize the specific role of MMPs in cancer progression.
  • To present an overview of preclinical and clinical studies involving matrix metalloproteinase inhibitors (MMPIs) and discuss their future therapeutic potential.

Main Methods:

  • Review of existing literature on ECM degradation and MMPs.

Related Experiment Videos

  • Analysis of preclinical data from studies on MMPIs.
  • Evaluation of early clinical trial results for MMPIs.

    • Main Results:

    • MMPs are key enzymes involved in ECM degradation, promoting tumor invasion and metastasis.
    • Numerous MMPIs have been developed, with several undergoing clinical evaluation.
    • Initial clinical studies with MMPIs have yielded preliminary results that warrant further investigation.

    Conclusions:

    • Targeting MMPs with MMPIs represents a potential therapeutic strategy for cancer.
    • Further research and clinical trials are necessary to establish the efficacy and safety of MMPIs.
    • The future perspective for MMPIs in cancer treatment is cautiously optimistic, pending further data.